BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Caraceni P, Vargas V, Solà E, Alessandria C, de Wit K, Trebicka J, Angeli P, Mookerjee RP, Durand F, Pose E, Krag A, Bajaj JS, Beuers U, Ginès P; Liverhope Consortium. The Use of Rifaximin in Patients With Cirrhosis. Hepatology 2021. [PMID: 33421158 DOI: 10.1002/hep.31708] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Bruneau A, Hundertmark J, Guillot A, Tacke F. Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases. Front Med (Lausanne) 2021;8:725390. [PMID: 34650994 DOI: 10.3389/fmed.2021.725390] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Sauerbruch T, Hennenberg M, Trebicka J, Beuers U. Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction. Front Physiol 2021;12:718783. [PMID: 34393832 DOI: 10.3389/fphys.2021.718783] [Reference Citation Analysis]
3 Cheng J, Chen Y, Cao W, Zuo G. Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?: A meta-analysis. Medicine (Baltimore) 2021;100:e28232. [PMID: 34941089 DOI: 10.1097/MD.0000000000028232] [Reference Citation Analysis]
4 Xiang J, Chi Y, Han J, Shi X, Cai Y, Xiang H, Xie Q. Intestinal Microbiota Contributes to the Improvement of Alcoholic Hepatitis in Mice Treated With Schisandra chinensis Extract. Front Nutr 2022;9:822429. [DOI: 10.3389/fnut.2022.822429] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Bloom PP, Tapper EB, Young VB, Lok AS. Microbiome therapeutics for hepatic encephalopathy. J Hepatol 2021;75:1452-64. [PMID: 34453966 DOI: 10.1016/j.jhep.2021.08.004] [Reference Citation Analysis]
6 Saboo K, Petrakov NV, Shamsaddini A, Fagan A, Gavis EA, Sikaroodi M, McGeorge S, Gillevet PM, Iyer RK, Bajaj JS. Stool microbiota are superior to saliva in distinguishing cirrhosis and hepatic encephalopathy using machine learning. J Hepatol 2021:S0168-8278(21)02183-8. [PMID: 34793867 DOI: 10.1016/j.jhep.2021.11.011] [Reference Citation Analysis]
7 Yukawa‐muto Y, Kamiya T, Fujii H, Mori H, Toyoda A, Sato I, Konishi Y, Hirayama A, Hara E, Fukuda S, Kawada N, Ohtani N. Distinct responsiveness to rifaximin in patients with hepatic encephalopathy depends on functional gut microbial species. Hepatology Communications. [DOI: 10.1002/hep4.1954] [Reference Citation Analysis]
8 Enomoto M, Kaji K, Nishimura N, Fujimoto Y, Murata K, Takeda S, Tsuji Y, Fujinaga Y, Takaya H, Kawaratani H, Namisaki T, Akahane T, Yoshiji H. Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitis. Dig Liver Dis 2022:S1590-8658(22)00257-2. [PMID: 35514019 DOI: 10.1016/j.dld.2022.04.012] [Reference Citation Analysis]
9 Wang N, Yao W, Ma R, Ren F. The efficacy of a multistrain probiotic on cognitive function and risk of falls in patients with cirrhosis: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e25535. [PMID: 33879696 DOI: 10.1097/MD.0000000000025535] [Reference Citation Analysis]
10 Pose E, Solà E, Lozano JJ, Juanola A, Sidorova J, Zaccherini G, de Wit K, Uschner F, Tonon M, Kazankov K, Jiménez C, Campion D, Napoleone L, Ma AT, Carol M, Morales-Ruiz M, Alessandria C, Beuers U, Caraceni P, Francoz C, Durand F, Mookerjee RP, Trebicka J, Vargas V, Piano S, Watson H, Abraldes JG, Kamath PS, Davis MM, Ginès P; investigators of the LIVERHOPE Consortium. Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis. Hepatol Commun 2021. [PMID: 34964311 DOI: 10.1002/hep4.1881] [Reference Citation Analysis]
11 Shamsaddini A, Gillevet PM, Acharya C, Fagan A, Gavis E, Sikaroodi M, McGeorge S, Khoruts A, Albhaisi S, Fuchs M, Sterling RK, Bajaj JS. Impact of Antibiotic Resistance Genes in Gut Microbiome of Patients With Cirrhosis. Gastroenterology 2021;161:508-521.e7. [PMID: 33857456 DOI: 10.1053/j.gastro.2021.04.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Ballester M, Gallego J, Fiorillo A, Casanova-ferrer F, Giménez-garzó C, Escudero-garcía D, Tosca J, Ríos M, Montón C, Durbán L, Ballester J, Benlloch S, Urios A, San-miguel T, Kosenko E, Serra M, Felipo V, Montoliu C. Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-06416-z] [Reference Citation Analysis]
13 Blesl A, Stadlbauer V. The Gut-Liver Axis in Cholestatic Liver Diseases. Nutrients 2021;13:1018. [PMID: 33801133 DOI: 10.3390/nu13031018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Liu J, Yang D, Wang X, Asare PT, Zhang Q, Na L, Shao L. Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases. Front Cell Infect Microbiol 2022;12:774335. [DOI: 10.3389/fcimb.2022.774335] [Reference Citation Analysis]
15 Caraceni P, Abraldes JG, Ginès P, Newsome PN, Sarin SK. The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery. J Hepatol 2021;75 Suppl 1:S118-34. [PMID: 34039483 DOI: 10.1016/j.jhep.2021.01.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]